Original articleStroke volume measurements with first-pass dynamic positron emission tomography: Comparison with cardiovascular magnetic resonance
Section snippets
Study Population
Subjects included in this study were recruited consecutively from various study protocols investigating myocardial perfusion, for which they underwent both dynamic H215O PET and CMR. The study population consisted of 59 subjects: 38 healthy volunteers or patients with diabetes without systolic LV dysfunction (mean age, 54 ± 8 years, ± SD), 6 patients with idiopathic dilated cardiomyopathy (DCM; mean age, 60 ± 9 years, ± SD), and 15 patients with hypertrophic cardiomyopathy (HCM; mean age, 57 ±
Hemodynamics and LV Dimensions
Mean heart rate (63 ± 11 vs 65 ± 10 beats · min−1, P = NS) and mean arterial pressure (88 ± 9 vs 89 ± 16 mmHg, P = NS) were similar during the PET and CMR studies. The CMR-derived mean LVEDV and LVESV were 182 ± 55 mL and 83 ± 59 mL, respectively, yielding a mean LVEF of 57 ± 14% (range, 9%-74%).
CO and Forward SV Measurements
Table 1 lists the PET and CMR estimated forward CO and forward SV measurements. The CMR estimated forward SV ranged from 34 to 164 mL (mean, 81 ± 20 mL). The CMR-obtained forward SV was significantly
Discussion
The present study was conducted to validate the previously reported use of first-pass dynamic PET using H215O in estimating forward SV in a large group of subjects with a wide range of cardiac function. The results suggest that, when taking aorta velocity-encoded phase-contrast CMR as a reference, this approach results in an overestimation of SV. Furthermore, although significant, the correlation between techniques is moderate at best. In addition, the extent of overestimation is related to
References (18)
- et al.
Measurement of left ventricular volumes and function with O-15-labeled carbon monoxide gated positron emission tomography: comparison with magnetic resonance imaging
J Nucl Cardiol
(2005) - et al.
Simultaneous cardiac output and regional myocardial perfusion determination with PET and nitrogen 13 ammonia
J Nucl Cardiol
(2003) - et al.
Magnetic resonance measurement of velocity and flow: technique, validation, and cardiovascular applications
Am Heart J
(1993) - et al.
Comparison of gated PET with MRI for evaluation of left ventricular function in patients with coronary artery disease
J Nucl Med
(2004) - et al.
Quantitative evaluation of myocardial blood flow and ejection fraction with a single dose of (13)NH(3) and gated PET
J Nucl Med
(2002) - et al.
Measurement of ventricular volumes and function: a comparison of gated PET and cardiovascular magnetic resonance
J Nucl Med
(2002) - et al.
Noninvasive determination of myocardial blood flow, oxygen consumption and efficiency in normal humans by carbon-11 acetate positron emission tomography imaging
Eur J Nucl Med
(1999) - et al.
Simple and accurate assessment of forward cardiac output by use of 1-(11)C-acetate PET verified in a pig model
J Nucl Med
(2003) - et al.
Measurement of cardiac output with first-pass determination during rubidium-82 PET myocardial perfusion imaging
Eur J Nucl Med
(1996)
Cited by (5)
First-Pass Techniques Applied to Standard Dynamic Cardiac PET: A reappraisal of Old Invasive Techniques to Assess Cardiac Function
2020, Seminars in Nuclear MedicineCitation Excerpt :Here a rapid (<2 seconds) infusion was used in combination with an input function from the RV and, compared to invasive thermodilution, near-perfect correlations (r = 0.98, P < 0.001) were found under baseline conditions, dobutamine stress, reduced cardiac contractility, and increased vascular resistance. Of interest, the first attempt with 15O-water provided discouraging results in the same year (r = 0.37, P < 0.01,25). Consecutive patients undergoing both 15O-water PET and CMR were included, acquiring data in a mixed cohort of dilated or hypertrophic cardiomyopathy patients.
Rapid decrease in delivery of chemotherapy to tumors after anti-vegf therapy: Implications for scheduling of anti-angiogenic drugs
2012, Cancer CellCitation Excerpt :A single infusion of bevacizumab did not affect systolic and diastolic blood pressure during the first 4 days (Figures 4A and 4B). Median cardiac output as derived from first pass dynamic [15O]H2O PET scans (Knaapen et al., 2008), however, showed a trend toward a reduction at day 4 (from 6.9 l·min−1 to 6.0 l·min−1; N = 9; p value = 0.051; Figure 4C). As inhibitors of VEGF/VEGFR-2 signaling may induce so-called rarefaction (Mourad et al., 2008), that is, a reduction in the number of arterioles or capillaries within vascular beds of various tissues (e.g., muscle and skin), muscle perfusion in the erector spinae, as well as capillary density in the skin, were measured.
Left ventricle function assessment using gated first-pass <sup>18</sup>F-FDG PET: Validation against equilibrium radionuclide angiography
2021, Journal of Nuclear Cardiology